Global Longlife

What does Global Longlife do?

Global Longlife Hospital and Research Ltd is a micro-cap company in the hospital industry, reporting net sales of 12 Cr and a net profit of 1 Cr for March 2023. It was incorporated in 2012 and became a public company in 2021, with a market cap of Rs 33 Cr.

Overview: <BR>Global Longlife Hospital and Research Ltd operates in the hospital industry and is classified as a micro-cap company.<BR><BR>History: <BR>The company was originally incorporated as "Global Longlife Hospital and Research Private Limited" in 2012 and later converted to a public limited company in 2021. The latest quarterly results reported net sales and net profit for March 2023.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 12 Cr (Quarterly Results - Mar 2023) <BR>Most recent Net Profit: 1 Cr (Quarterly Results - Mar 2023) <BR>Market-cap value: Rs 33 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 33.00 <BR>Industry P/E: N/A <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.52 <BR>Return on Equity: 0.84% <BR>Price to Book: 1.39 <BR><BR>Contact Details: <BR>No Company Details Available <BR>Registrar Address: Not available.

When is the next results date for Global Longlife?

No Upcoming Board Meetings

Has Global Longlife declared dividend?

No Dividend History Available

Who are the peers of the Global Longlife?

Global Longlife's peers include Max Healthcare, Apollo Hospitals, Fortis Health, and others. While Soni Medicare leads in 1-year returns at 124.83%, Global Longlife has the lowest return at -9.79% and exhibits below-average growth and capital structure compared to its peers.

Peers: The peers of Global Longlife are Max Healthcare, Apollo Hospitals, Fortis Health., Narayana Hrudaya, Global Health, KK Shah Hospital, Soni Medicare, Broach, and Nidan Laborator.<BR><BR>Quality Snapshot: Excellent management risk is observed at Max Healthcare, Apollo Hospitals, and Narayana Hrudaya, while Good management risk is found at Global Health and the rest. Average growth is noted at Fortis Health., Narayana Hrudaya, and Global Health, whereas Below Average growth is seen at Global Longlife, KK Shah Hospital, Soni Medicare, and the rest. Excellent capital structure is present at Max Healthcare and Global Health, while Good capital structure is found at Fortis Health. and KK Shah Hospital, with Below Average capital structure at Global Longlife, Soni Medicare, Nidan Laborator., and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Soni Medicare at 124.83%, while Global Longlife has the lowest at -9.79%. This indicates that Global Longlife's return is significantly lower than its peers. Additionally, the six-month return is negative for Global Longlife, KK Shah Hospital, and Broach.

Is Global Longlife overvalued or undervalued?

As of February 1, 2024, Global Longlife is considered risky and overvalued, with a PE ratio of 31.43 and negative EV to EBITDA, raising concerns about its profitability and financial health compared to peers like Max Healthcare and Apollo Hospitals.

As of 1 February 2024, the valuation grade for Global Longlife has moved from very attractive to risky. The company is currently assessed as overvalued. Key ratios include a PE ratio of 31.43, an EV to EBITDA of -10.52, and a PEG ratio of 0.29, indicating potential concerns regarding profitability and growth expectations.<BR><BR>In comparison to its peers, Global Longlife's PE ratio is significantly lower than that of Max Healthcare Institute Ltd., which stands at 100.29, and Apollo Hospitals Enterprise Ltd. at 69.03, both of which are categorized as very expensive. This suggests that while Global Longlife may appear less expensive on a PE basis, its negative EV to EBITDA and low ROE of 0.84% raise red flags about its financial health and operational efficiency. Additionally, the company's stock has underperformed the Sensex over the past year, further reinforcing the notion of overvaluation.

What is the technical trend for Global Longlife?

As of May 15, 2025, Global Longlife's trend is mildly bearish, influenced by daily moving averages and mixed signals from MACD and Bollinger Bands, suggesting a cautious outlook.

As of 15 May 2025, the technical trend for Global Longlife has changed from bearish to mildly bearish. The current stance is mildly bearish, primarily driven by the daily moving averages indicating a bearish trend. The weekly MACD shows a mildly bullish signal, but this is countered by the monthly MACD being mildly bearish. Additionally, Bollinger Bands on a monthly basis are bearish, while the weekly Bollinger Bands are mildly bullish. The KST is bullish on a weekly basis, yet the Dow Theory indicates no trend in both weekly and monthly time frames. Overall, the mixed signals suggest a cautious outlook with a slight bearish bias.

Who are in the management team of Global Longlife?

As of March 2023, the management team of Global Longlife includes Sureshkumar Babulal Jani (Chairman/Executive Director), Dhruv Sureshkumar Jani (Managing Director), Sucheta Dhruvkumar Jani (Non-Executive & Non-Independent Director), Manasvi Manu Thapar (Independent Non-Executive Director), and Sandeep M Shah (Independent Non-Executive Director).

As of March 2023, the management team of Global Longlife includes the following individuals:<BR><BR>1. Sureshkumar Babulal Jani - Chairman / Executive Director<BR>2. Dhruv Sureshkumar Jani - Managing Director<BR>3. Sucheta Dhruvkumar Jani - Non-Executive & Non-Independent Director<BR>4. Manasvi Manu Thapar - Independent Non-Executive Director<BR>5. Sandeep M Shah - Independent Non-Executive Director<BR><BR>These members play various roles in the company's governance and strategic direction.

Who are the top shareholders of the Global Longlife?

The top shareholders of Global Longlife are Dhruv Sureshkumar Jani with 37.13%, followed by public shareholder Yogeshkumar Rasiklal Sanghavi at 3.67%, and individual investors collectively holding 33.71%. There are no mutual funds or foreign institutional investors in the company.

The top shareholders of Global Longlife include Dhruv Sureshkumar Jani, who is the promoter with the highest holding at 37.13%. The highest public shareholder is Yogeshkumar Rasiklal Sanghavi, holding 3.67%. Additionally, individual investors collectively hold 33.71% of the company's shares. There are no mutual funds or foreign institutional investors currently holding shares in the company.

How big is Global Longlife?

As of 24th July, Global Longlife Hospital and Research Ltd has a market capitalization of 27.00 Cr and reported net sales of 23.50 Cr and net profit of 1.83 Cr over the latest two quarters. Shareholder's funds are valued at 25.93 Cr, with total assets of 39.51 Cr.

As of 24th July, <BR><BR>Market Cap: Global Longlife Hospital and Research Ltd has a market capitalization of 27.00 Cr and is classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest two quarters, which are March 2023 and September 2022, is 23.50 Cr. The sum of Net Profit for the same quarters is 1.83 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the latest annual data is March 2024. Shareholder's Funds are valued at 25.93 Cr, while Total Assets amount to 39.51 Cr.

How has been the historical performance of Global Longlife?

Global Longlife has experienced a significant decline in financial performance, with net sales dropping from 32.82 Cr in Mar'22 to 0.58 Cr in Mar'25, and operating profit turning negative at -4.16 Cr. Total assets and liabilities have also decreased, while cash flow from operations remains negative, indicating ongoing operational challenges.

Answer:<BR>The historical performance of Global Longlife shows a significant decline in net sales and operating income over the past few years, with net sales dropping from 32.82 Cr in Mar'22 to just 0.58 Cr in Mar'25. Total operating income followed a similar trend, decreasing from 32.82 Cr in Mar'22 to 0.58 Cr in Mar'25. The company experienced a negative operating profit (PBDIT) in Mar'25 at -4.16 Cr, contrasting with a positive operating profit of 8.03 Cr in Mar'22. Profit before tax also saw a decline, moving from 5.71 Cr in Mar'22 to 0.10 Cr in Mar'25, while profit after tax improved slightly to 0.20 Cr in Mar'25 from a loss of 2.19 Cr in Mar'24. The company's total assets decreased from 73.79 Cr in Mar'23 to 24.50 Cr in Mar'25, and total liabilities also fell from 39.51 Cr in Mar'24 to 24.50 Cr in Mar'25. Cash flow from operating activities remained negative, indicating ongoing challenges in generating cash from core operations.<BR><BR>Breakdown:<BR>Global Longlife's financial trajectory reveals a concerning decline in key metrics. Net sales have plummeted from 32.82 Cr in Mar'22 to a mere 0.58 Cr in Mar'25, reflecting a drastic reduction in operational capacity. This decline is mirrored in total operating income, which fell from 32.82 Cr to 0.58 Cr over the same period. The operating profit (PBDIT) transitioned from a healthy 8.03 Cr in Mar'22 to a negative 4.16 Cr in Mar'25, indicating significant operational challenges. Profit before tax also deteriorated, moving from 5.71 Cr to 0.10 Cr, while profit after tax showed a slight recovery to 0.20 Cr in Mar'25 from a loss in the previous year. The company's total assets and liabilities have both decreased, with total assets dropping from 73.79 Cr to 24.50 Cr and total liabilities from 39.51 Cr to 24.50 Cr, suggesting a shrinking balance sheet. Cash flow from operating activities has remained negative, highlighting ongoing difficulties in generating cash from operations.

Why is Global Longlife Hospital and Research Ltd falling/rising?

As of 10-Feb, Global Longlife Hospital and Research Ltd's stock price is Rs. 12.85, reflecting a significant decline of -4.96%. The stock has underperformed the Sensex, with a year-to-date drop of -49.11% and a 52-week low, indicating ongoing weakness in price momentum despite increased investor participation.

As of 10-Feb, Global Longlife Hospital and Research Ltd is experiencing a decline in its stock price, currently at Rs. 12.85, which represents a change of -0.67 or -4.96%. The stock has been underperforming significantly compared to the benchmark Sensex, with a 1-week decline of -7.55% and a staggering -41.54% drop over the past month. Year-to-date, the stock has fallen by -49.11%, and over the past year, it has decreased by -57.87%, while the Sensex has gained 9.01% in the same period.<BR><BR>Today, the stock hit a new 52-week low, indicating a continued downward trend. It has been losing for the last two days, with a total decline of -9.7% during this period. Furthermore, the stock is trading below its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which typically suggests weakness in price momentum.<BR><BR>Despite a rise in investor participation, with delivery volume increasing by 83.45% on February 6, the overall performance remains negative, as the stock has underperformed its sector by -5.63% today. This combination of factors contributes to the ongoing decline in the stock price of Global Longlife Hospital and Research Ltd.

Which are the latest news on Global Longlife?